Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Lassa fever vaccine trial in adults and children in West Africa
PACTR202210840719552Phase 2Recruiting
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 3
01
Overview
Phase 2 trial of rVSV∆G-LASV-GPC in Lassa fever (2 arms), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Grade 3 or higher reactogenicity, Investigational product-related Grade 2 or higher unsolicited adverse events and 3 more. Started Aug 2023; status: recruiting.
02
Drugs
rVSV∆G-LASV-GPC
03
Conditions
Lassa fever
Beyond the preview
Go deeper on PACTR202210840719552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202210840719552.